Search results for "Prognosis."

showing 10 items of 2044 documents

Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis

2015

Background and Objectives Lymph node involvement is common in thyroid cancer, but the system of staging does not consider the histological features of lymph node metastases. We conducted a meta-analysis to investigate the prognostic role of extranodal extension (ENE) in thyroid cancer patients. Methods We ran PubMed and SCOPUS searches without language restrictions. Prospective studies reporting data on overall mortality, cancer-specific mortality, or disease recurrence including thyroid cancer patients, in which cases with ENE (ENE+) were compared with those with only intranodal disease (ENE-) were eligible. Data were summarized using risk ratios (RR) for number of deaths/recurrences, and …

Oncologyextranodal extension; prognosis; survival; thyroid cancerLymphatic MetastasisMedicine (all)thyroid cancerextranodal extensionHumansSurgeryprognosisThyroid Neoplasmsextranodal extension; prognosis; survival; thyroid cancer; Humans; Lymphatic Metastasis; Prognosis; Thyroid Neoplasms; Surgery; Oncology; Medicine (all)survival: extranodal extension
researchProduct

Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.

2016

Introduction: The extranodal extension (ENE) of nodal metastases (the extension of neoplastic cells through the nodal capsule into the perinodal soft tissue) is a histological feature that has been considered a prognostic factor in several cancers, but the role in gastric cancer was not yet investigated. We aimed to investigate the prognostic role of ENE in patients affected by gastric cancer through a systematic review and meta-analysis. Material and Methods: Two independent authors searched major databases until 09/30/2015 to identify studies providing data on gastric cancer patients’ prognostic parameters and comparing patients with ENE (ENE+) vs intra-nodal extension (ENE−). The data we…

Oncologymedicine.medical_specialty03 medical and health sciencesNodal Metastases Extranodal Extension Gastric Cancer0302 clinical medicineextranodal extension nodal metastases gastric cancerRecurrenceStomach NeoplasmsInternal medicineExtranodal extensionmedicineOdds RatioHumansGastric cancer . ENE . Extranodal extensionENE; Extranodal extension; Gastric cancer; Lymph node metastasis; Surgery; GastroenterologyProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelNodal MetastasesHazard ratioConfoundingGastroenterologyCancerOdds ratiomedicine.diseasePrognosisConfidence interval030220 oncology & carcinogenesisMeta-analysisRelative riskLymphatic MetastasisENE030211 gastroenterology & hepatologySurgeryLymph NodesNeoplasm Recurrence LocalbusinessGastric cancerJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
researchProduct

Staging systems of hepatocellular carcinoma: A review of literature

2013

Hepatocellular carcinoma (HCC) is a major health problem with a high incidence and mortality all over the world. Natural history of HCC is severe and extremely variable, and prognostic factors influencing outcomes are incompletely defined. Over time, many staging and scoring systems have been proposed for the classification and prognosis of patients with HCC. Currently, the non-ideal predictive performance of existing prognostic systems is secondary to their inherent limitations, as well as to a non-universal reproducibility and transportability of the results in different populations. New serological and histological markers are still under evaluation with promising results, but they requi…

Oncologymedicine.medical_specialtyAsiaCarcinoma HepatocellularTime FactorsMedical OncologyGastroenterologyInternal medicineBiomarkers TumorHumansMedicineTopic HighlightNeoplasm Stagingbusiness.industryIncidence (epidemiology)Liver NeoplasmsGastroenterologyExternal validationReproducibility of ResultsGeneral MedicinePrognosismedicine.diseasedigestive system diseasesEuropeNatural historyHepatocellular carcinomabusinessAlgorithmsWorld Journal of Gastroenterology
researchProduct

Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features …

2009

A new classification based on gene expression profiling or immunohistochemical (IHC) characteristics may replace current histopathological classifications and predict better clinical outcomes. We used IHC markers to classify incident cases ascertained by the Palermo Breast Cancer Registry (2002-2004) into four subtypes: luminal-A (ER+ or PgR+ and HER2/neu-); luminal-B (ER+ or PgR+, HER2/neu+); basal-like (ER-, PgR-, HER2/neu-); and HER2+/ER- (HER2/neu+, ER-, PgR-). We evaluated HER2/neu, ER and PgR in 1300/1985 (65%) cases. The most common IHC-subtype was luminal-A (68%), whereas luminal-B, basal-like, and HER2+/ER- accounted for 14%, 13%, and 5%, respectively. IHC-subtypes were not associa…

Oncologymedicine.medical_specialtyBreast NeoplasmsPopulation basedGeneral Biochemistry Genetics and Molecular BiologyBreast tumorBreast cancerHistory and Philosophy of ScienceInternal medicinemedicineHumansRegistriesskin and connective tissue diseasesGrading (tumors)DemographyGynecologyTumor sizebusiness.industryGeneral NeuroscienceGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistryCancer registryMenopauseItalyReceptors EstrogenPopulation SurveillanceImmunohistochemistryFemalebusinessReceptors ProgesteroneAnnals of the New York Academy of Sciences
researchProduct

Detection methods predict differences in biology and survival in breast cancer patients

2012

Abstract Background The aim of this study was to measure the biological characteristics involved in tumorigenesis and the progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences. Methods For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities in a series of 130 symptomatic and 161 screen-detected tumors. Results After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96) and had high estrogen and progesterone receptor concentrations more …

Oncologymedicine.medical_specialtyCancer ResearchSurvivalProliferationBreast NeoplasmsApoptosisKaplan-Meier Estimatemedicine.disease_causelcsh:RC254-282Breast cancerBreast cancerSurgical oncologyInternal medicineDetection methodsmedicineGeneticsHumansMammographyEarly Detection of CancerProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryProportional hazards modelDisease progressionCase-control studyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosismedicine.diseaseImmunohistochemistryOncologyCase-Control StudiesDisease ProgressionImmunohistochemistryFemalebusinessCarcinogenesisMammographyResearch Article
researchProduct

A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

2017

Background & Aims: Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis were to estimate the recurrence and survival probabilities of HCV-related early HCC following complete response after potentially curative treatment and to identify predictors of recurrence and survival. Methods: Studies reporting time-dependent outcomes (HCC recurrence or death) after potentially curative treatment of HCV-relat…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularrecurrenceHepatitis C virusmedicine.medical_treatmentmedicine.disease_causesurvivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyhepatocellular carcinoma; prognosis; recurrences; survivalHumansSurvival analysisHepatologyrecurrencesbusiness.industryLiver Neoplasmshepatocellular carcinomaHepatologymedicine.diseaseHepatitis Chepatocellular carcinoma; prognosis; recurrences; survival; Hepatology030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinoma030211 gastroenterology & hepatologyprognosisNeoplasm Recurrence LocalbusinessAdjuvantprognosi
researchProduct

Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia

2008

Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgVH mutational status, widely differing clinical courses were revealed. Since IgVH sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgVH mutational status seems an important priority. In the present study, we proposed the use of Cryptochrome- 1 as a new prognostic marker in early-stage chronic lymphocytic leukemia. Seventy patients (Binet stage A, without treatment) were included in the study. We correlated Cryptochrome-1 mRNA with well established prognostic markers such as IgVH mu…

Oncologymedicine.medical_specialtyChronic lymphocytic leukemiaIgV(H)ZAP70 LPL IgVHImmunoglobulin E:CIENCIAS MÉDICAS ::Patología::Hematología [UNESCO]Prognostic markerPredictive Value of TestsInternal medicinemedicineHumansUNESCO::CIENCIAS MÉDICAS ::Patología::HematologíaRNA MessengerStage (cooking)HematologybiologyFlavoproteinsZAP70CancerHematologyCryptochrome-1medicine.diseasePrognosis:CIENCIAS MÉDICAS [UNESCO]Leukemia Lymphocytic Chronic B-CellCryptochromesLeukemiaUNESCO::CIENCIAS MÉDICAS ::Patología::OncologíaImmunologyUNESCO::CIENCIAS MÉDICASbiology.proteinZAP70Brief ReportsChronic lymphocytic leukemiaAntibodyLPL:CIENCIAS MÉDICAS ::Patología::Oncología [UNESCO]BiomarkersCryptochrome-1 ; Prognostic marker ; Chronic lymphocytic leukemia ; ZAP70 LPL IgVH
researchProduct

First results for resetting the antitumor immune response by immune corrective surgery in colon cancer.

1998

BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure. METHODS: In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved …

Oncologymedicine.medical_specialtyColorectal cancerAntibodies NeoplasmImmune systemAntigenAntigens NeoplasmInternal medicineCarcinomamedicineHumansProspective StudiesLymph nodeNeoplasm StagingAntigen PresentationbiologyFollicular dendritic cellsbusiness.industryGeneral Medicinemedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureTreatment OutcomeRadioimmunodetectionImmunologyAntibody FormationColonic Neoplasmsbiology.proteinLymph Node ExcisionSurgeryLymphImmunotherapyLymph NodesAntibodyNeoplasm Recurrence LocalbusinessAmerican journal of surgery
researchProduct

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.

2010

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentColonoscopyPharmacotherapyMeta-Analysis as TopicRisk FactorsInternal medicineEpidemiologyAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary PreventionHumansSurvival analysisEarly Detection of CancerNeoplasm StagingRandomized Controlled Trials as TopicChemotherapymedicine.diagnostic_testbusiness.industryIncidenceCancerHematologyColonoscopymedicine.diseasePrognosisSurvival AnalysisSurgeryCarcinoembryonic AntigenEuropeTreatment OutcomeOncologyChemotherapy AdjuvantColonic NeoplasmsbusinessAdjuvantFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.

2008

During the last two decades, considerable efforts have been made to improve the prevention, early diagnosis and therapy of colorectal cancer by gaining enhanced insights into disease-specific pathogenesis. Along these lines, tumor-infiltrating immune cells turned out to be critical indicators for an efficient antitumor immune response and the number and type of tumor-infiltrating immune cells determined the resulting tumor prognosis. This review aims to describe the prognostic relevance of the different subsets of tumor-infiltrating immune cells and highlights their specific function in the complex process of immune system-mediated rejection of colorectal cancer cells. Considering the clini…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentT cellAntineoplastic AgentsCancer VaccinesT-Lymphocytes RegulatoryPathogenesisImmune systemLymphocytes Tumor-InfiltratingAntigenAntigens NeoplasmInternal medicinemedicineBiomarkers TumorHumansPharmacology (medical)biologybusiness.industryMacrophagesAntibodies MonoclonalImmunotherapyDendritic Cellsmedicine.diseasePrognosisKiller Cells NaturalCytokinemedicine.anatomical_structureEarly DiagnosisOncologybiology.proteinImmunotherapyAntibodybusinessColorectal NeoplasmsImmunologic MemoryExpert review of anticancer therapy
researchProduct